Tangeretin induces cell cycle arrest and apoptosis through upregulation of PTEN expression in glioma cells

Biomedicine and Pharmacotherapy

Volumn 81, Issue , 2016, Pages 491-496

  Ma, Li Li ^a,b   Wang, Da wei ^b   Yu, Xu Dong ^c   Zhou, Yan Ling ^d  

^a YANTAISHAN HOSPITAL   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

^c Longkou City People's Hospital   (China)

^d BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Glioblastoma; PTEN and apoptosis; Tangeretin

Indexed keywords

ANTINEOPLASTIC AGENT; CDC2 PROTEIN; CYCLIN D; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; TANGERETIN; UNCLASSIFIED DRUG; FLAVONE DERIVATIVE; PTEN PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BRAIN TUMOR; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TIME FACTOR; TUMOR CELL LINE;

APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; TIME FACTORS; UP-REGULATION;

EID: 84964907575     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.04.006     Document Type: Article

References (35)

1. Sathornsumetee S., Reardon D.A., Desjardins A., Quinn J.A., Vredenburgh J.J., Rich J.N. Molecularly targeted therapy for malignant glioma. Cancer 2007, 110:13-24.
2. Collins V.P. Gliomas. Cancer Surv. 1998, 32:37-51.
3. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J.P., Heese O., Reifenberger G., Weller M., Schackert G., German Glioma N. Long-term survival with glioblastoma multiforme. Brain 2007, 130:2596-2606.
4. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., Burkhard C., Schuler D., Probst-Hensch N.M., Maiorka P.C., Baeza N., Pisani P., Yonekawa Y., Yasargil M.G., Lutolf U.M., Kleihues P. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004, 64:6892-6899.
5. Das M., Mohanty C., Sahoo S.K. Ligand-based targeted therapy for cancer tissue. Expert Opin. Drug Deliv. 2009, 6:285-304.
6. Bianco R., Shin I., Ritter C.A., Yakes F.M., Basso A., Rosen N., Tsurutani J., Dennis P.A., Mills G.B., Arteaga C.L. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22:2812-2822.
7. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
8. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., Riggs B.L., Horvath S., Liau L.M., Cavenee W.K., Rao P.N., Beroukhim R., Peck T.C., Lee J.C., Sellers W.R., Stokoe D., Prados M., Cloughesy T.F., Sawyers C.L., Mischel P.S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353:2012-2024.
9. Mukhtar H. Chemoprevention: making it a success story for controlling human cancer. Cancer Lett. 2012, 326:123-127.
10. Steward W.P., Brown K. Cancer chemoprevention: a rapidly evolving field. Br. J. Cancer 2013, 109:1-7.
11. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65:6934-6942.
12. Arivazhagan L., Sorimuthu Pillai S. Tangeretin a citrus pentamethoxyflavone, exerts cytostatic effect via p53/p21 up-regulation and suppresses metastasis in 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinoma. J. Nutr. Biochem. 2014, 25:1140-1153.
13. Seo J., Lee H.S., Ryoo S., Seo J.H., Min B.S., Lee J.H. Tangeretin a citrus flavonoid, inhibits PGDF-bB-induced proliferation and migration of aortic smooth muscle cells by blocking AKT activation. Eur. J. Pharmacol. 2011, 673:56-64.
14. Hirano T., Abe K., Gotoh M., Oka K. Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes. Br. J. Cancer 1995, 72:1380-1388.
15. Datla K.P., Christidou M., Widmer W.W., Rooprai H.K., Dexter D.T. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport 2001, 12:3871-3875.
16. Lake B.G., Beamand J.A., Tredger J.M., Barton P.T., Renwick A.B., Price R.J. Inhibition of xenobiotic-induced genotoxicity in cultured precision-cut human and rat liver slices. Mutat. Res. 1999, 440:91-100.
17. Walle T. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass?. Semin. Cancer Biol. 2007, 17:354-362.
18. Xiu L.J., Sun D.Z., Jiao J.P., Yan B., Qin Z.F., Liu X., Wei P.K., Yue X.Q. Anticancer effects of traditional Chinese herbs with phlegm-eliminating properties - An overview. J. Ethnopharmacol. 2015, 172:155-161.
19. Appel J.M., Nielsen D., Zerahn B., Jensen B.V., Skagen K. Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncol. 2007, 46:576-580.
20. Lal R., Enting D., Kristeleit H. Systemic treatment of non-small-cell lung cancer. Eur. J. Cancer 2011, 47(Suppl. (3)):S375-7.
21. Gupta S., Mukhtar H. Chemoprevention of skin cancer: current status and future prospects. Cancer Metastasis Rev. 2002, 21:363-380.
22. Nyberg K.A., Michelson R.J., Putnam C.W., Weinert T.A. Toward maintaining the genome: dNA damage and replication checkpoints. Annu. Rev. Genet. 2002, 36:617-656.
23. Ferreira C.G., Epping M., Kruyt F.A., Giaccone G. Apoptosis: target of cancer therapy. Clin. Cancer Res. 2002, 8:2024-2034.
24. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004, 73:39-85.
25. Labbe J.C., Lee M.G., Nurse P., Picard A., Doree M. Activation at M-phase of a protein kinase encoded by a starfish homologue of the cell cycle control gene cdc2+. Nature 1988, 335:251-254.
26. Borgne A., Ostvold A.C., Flament S., Meijer L. Intra-m phase-promoting factor phosphorylation of cyclin B at the prophase/metaphase transition. J. Biol. Chem. 1999, 274:11977-11986.
27. Zhan Q., Antinore M.J., Wang X.W., Carrier F., Smith M.L., Harris C.C., Fornace A.J. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 1999, 18:2892-2900.
28. Vikhanskaya F., Erba E., D'Incalci M., Broggini M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res. 1994, 22:1012-1017.
29. Stewart N., Hicks G.G., Paraskevas F., Mowat M. Evidence for a second cell cycle block at G2/M by p53. Oncogene 1995, 10:109-115.
30. Huang C., Ma W.Y., Goranson A., Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999, 20:237-242.
31. Myzak M.C., Hardin K., Wang R., Dashwood R.H., Ho E. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis 2006, 27:811-819.
32. She Q.B., Bode A.M., Ma W.Y., Chen N.Y., Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res. 2001, 61:1604-1610.
33. Seth R., Yang C., Kaushal V., Shah S.V., Kaushal G.P. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J. Biol. Chem. 2005, 280:31230-31239.
34. Schuler M., Bossy-Wetzel E., Goldstein J.C., Fitzgerald P., Green D.R. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J. Biol. Chem. 2000, 275:7337-7342.
35. Pal S., Bhattacharjee A., Ali A., Mandal N.C., Mandal S.C., Pal M. Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond) 2014, 11:23.